



Fig. S2.

Progression-free survival – patients with TGCT.

Efficacy-evaluable population. Progression-free survival was defined as the number of days from the first day of treatment to the first documented disease progression or date of death, whichever occurred first. If no disease progression or death was documented prior to study termination, analysis cutoff, or the start of confounding anticancer therapy, progression-free survival was censored at the date of last evaluable tumor assessment.

PVNS = pigmented villonodular synovitis; TGCT = tenosynovial giant cell tumor.